Foresite Life Sciences withdrew a planned offering of 25 million units, according to a letter the SPAC sent Friday to the SEC.
Launched by Foresight Capital, the SPAC had planned to list on the Nasdaq with Jefferies acting as sole book-running manager for the offering.
Foresite in its iniital registration with the regulator in February last year cited plans to acquire a business in the biotechnology and life science infrastructure sectors. President, CEO and Director Jim Tananbaum founded Foresight Capital in 2011. Read more.
